Aethlon Medical Announces New Pre-Clinical Data on Hemopurifier® for Long COVID at Keystone Symposium

Reuters

06-09

Aethlon Medical Announces New Pre-Clinical Data on Hemopurifier® for Long COVID at Keystone Symposium

Aethlon Medical Inc., a company specializing in medical therapeutics for cancer and infectious diseases, has announced the acceptance of an abstract for a poster presentation at the Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes. The presentation will focus on new pre-clinical data regarding the Hemopurifier®, an investigational extracorporeal device designed to bind and remove harmful extracellular vesicles (EVs) from the blood. The data examines the device's ability to bind mannosylated EVs found in individuals with Long COVID. The presentation, led by Dr. Steven P. LaRosa, Chief Medical Officer of Aethlon Medical, will take place on August 12, 2025, at 19:30 MDT in Santa Fe, NM. Results have not yet been presented but will be available on the Aethlon Medical corporate website after the symposium.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA05364) on June 09, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2542094381"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2542094381\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2542094381?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-09 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2542094381","market":"nz","top_or_hot":-1,"title":"Aethlon Medical Announces New Pre-Clinical Data on Hemopurifier® for Long COVID at Keystone Symposium","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aethlon Medical Announces New Pre-Clinical Data on Hemopurifier® for Long COVID at Keystone Symposium\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/AEMD\">Aethlon Medical Inc</a>., a company specializing in medical therapeutics for cancer and infectious diseases, has announced the acceptance of an abstract for a poster presentation at the Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes. The presentation will focus on new pre-clinical data regarding the Hemopurifier®, an investigational extracorporeal device designed to bind and remove harmful extracellular vesicles (EVs) from the blood. The data examines the device's ability to bind mannosylated EVs found in individuals with Long COVID. The presentation, led by Dr. Steven P. LaRosa, Chief Medical Officer of Aethlon Medical, will take place on August 12, 2025, at 19:30 MDT in Santa Fe, NM. Results have not yet been presented but will be available on the Aethlon Medical corporate website after the symposium.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA05364) on June 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aethlon Medical Announces New Pre-Clinical Data on Hemopurifier® for Long COVID at Keystone Symposium</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAethlon Medical Announces New Pre-Clinical Data on Hemopurifier® for Long COVID at Keystone Symposium\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-09 20:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aethlon Medical Announces New Pre-Clinical Data on Hemopurifier® for Long COVID at Keystone Symposium\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/AEMD\">Aethlon Medical Inc</a>., a company specializing in medical therapeutics for cancer and infectious diseases, has announced the acceptance of an abstract for a poster presentation at the Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes. The presentation will focus on new pre-clinical data regarding the Hemopurifier®, an investigational extracorporeal device designed to bind and remove harmful extracellular vesicles (EVs) from the blood. The data examines the device's ability to bind mannosylated EVs found in individuals with Long COVID. The presentation, led by Dr. Steven P. LaRosa, Chief Medical Officer of Aethlon Medical, will take place on August 12, 2025, at 19:30 MDT in Santa Fe, NM. Results have not yet been presented but will be available on the Aethlon Medical corporate website after the symposium.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA05364) on June 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250609:nNDL1Zf8tz:1","article_id":"2542094381","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2542094381","pubTimestamp":1749470479,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Aethlon Medical Inc., a company specializing in medical therapeutics for cancer and infectious diseases, has announced the acceptance of an abstract for a poster presentation at the Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes. The presentation will focus on new pre-clinical data regarding the Hemopurifier, an investigational extracorporeal device designed to bind and remove harmful extracellular vesicles  from the blood. The data examines the device's ability to bind mannosylated EVs found in individuals with Long COVID. The presentation, led by Dr. Steven P. LaRosa, Chief Medical Officer of Aethlon Medical, will take place on August 12, 2025, at 19:30 MDT in Santa Fe, NM. Results have not yet been presented but will be available on the Aethlon Medical corporate website after the symposium.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","BK4568":"美国抗疫概念","BK4583":"猴痘概念","AEMD":"Aethlon Medical Inc"},"translate_title":"Aethlon Medical在Keystone研讨会上公布新冠后遗症血液净化器®的新临床前数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AEMD":0.9},"content_text":"Aethlon Medical Announces New Pre-Clinical Data on Hemopurifier® for Long COVID at Keystone Symposium\n    \n\nAethlon Medical Inc., a company specializing in medical therapeutics for cancer and infectious diseases, has announced the acceptance of an abstract for a poster presentation at the Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes. The presentation will focus on new pre-clinical data regarding the Hemopurifier®, an investigational extracorporeal device designed to bind and remove harmful extracellular vesicles (EVs) from the blood. The data examines the device's ability to bind mannosylated EVs found in individuals with Long COVID. The presentation, led by Dr. Steven P. LaRosa, Chief Medical Officer of Aethlon Medical, will take place on August 12, 2025, at 19:30 MDT in Santa Fe, NM. Results have not yet been presented but will be available on the Aethlon Medical corporate website after the symposium.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA05364) on June 09, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}